← FDA DRUG APPROVALS

FDA ANDA · ANDA214877

CHOLESTYRAMINE

Sponsor: AIPING PHARM INC

APPLICATION
ANDA214877
TYPE
ANDA
ORIGINAL APPROVAL
2022-01-21
LATEST ACTION
2022-01-21
ROUTE
ORAL
DOSAGE FORM
POWDER
MARKETING STATUS
Prescription

Products

CHOLESTYRAMINEPrescription
CHOLESTYRAMINE EQ 4GM RESIN/PACKET · POWDER · ORAL
CHOLESTYRAMINEPrescription
CHOLESTYRAMINE EQ 4GM RESIN/SCOOPFUL · POWDER · ORAL

Approval history

2022-01-21UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →